Pharmaceutical
Pfizer to acquire Metsera in $7.3 billion deal to enter obesity drug market
Pfizer announced Monday that it will acquire biotech firm Metsera in a deal worth up to $7.3 billion, including future milestone payments, as it works to secure a foothold in the booming obesity drug market. Under the agreement, Pfizer will pay $47.50 a share in cash for Metsera,